Denis Mulleman

Denis Mulleman is Professor of Rheumatology at the University of Tours and consultant at the Regional University Hospital of Tours, France. He is member of the Center for Molecular Biophysics, a research unit of the National Centre for scientific research (CNRS) at the Nanomedicines and Nanoprobes department. His main research is dedicated to pharmacology, immunogenicity of therapeutic antibodies in chronic inflammatory rheumatic diseases.

During the last 15 years his may duties were :

1) Coordinator of the Consortium «Monitoring of monoclonal Antibodies Group in Europe» (MAGE) for inflammatory diseases (Mai 2015-December 2017), supported by LE STUDIUM Loire Valley Institute for Advanced Studies (http://www.lestudium-ias.com)

2) Representative for his laboratory in the ABIRISK consortium (www.abirisk.eu) dedicated to immunogenicity to biopharmaceutical March 2012-March 2018.

3) co-leader of the key question N°3 of the Laboratory of Excellence MabImprove “How can antibodies efficacy can be increased using combinations ?“ with Laurent Gros (Inserm (http://mabimprove.univ-tours.fr/en/) (December 2017- December 2025)

4) Guest researcher at the University of Uppsala (Siv Jönsson and Mats Karlsson) at the department of pharmacometrics (sept 2019-August 2020), and Chair of the COST Action CA21147 ENOTTA European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases (November 2022-November 2026) https://enotta.eu/

His present projects are directed towards personalized medicine and advanced therapy medicinal product in chronic inflammatory diseases.